Patients in the B group were given berberine hydrochloride tables 0.3g tid orally or tube feed daily, until the 14th day of the study. Other treatments include general support therapy, oxygen therapy, antiviral drugs, in combination with antibiotics and small doses of glucocorticoids if necessary, nutritional and organ function support.

Patients in the C group were given montmorilonite orally if they presence of diarrhea. The other treatments were the same as in B group.

Berberine

COVID-19

Patients in the intervention group received berberine daily, regardless of gastrointestinal symptoms.If the patient has a serious drug-related adverse event, the drug will be discontinued and the patient will be excluded from the study.

Patients in the control group were routinely not given special treatment.However, if the patient has diarrhea symptoms, montmorillonite powder should be given orally.

Montmorrillonite

Nanjing Drum Tower Hospital

The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19

Including diarrhea in times/day, Bristol Stool Scale (the minimum 1 and maximum 7, a higher scores mean a worse outcome) and whether patient has any one of gastrointestinal symptoms (nausea, vomiting, abdominal pain, abdominal distension or diarrhoea).

evaluate inflammatory response, blood sample collected at 6:00am

evaluate the severity of the disease(the minimum 0 and maximum 24, a higher scores mean a worse outcome)

berberine/vėmimas

The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu